Boxer Capital Management LLC purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 250,000 shares of the company's stock, valued at approximately $3,958,000. Boxer Capital Management LLC owned about 0.62% of Keros Therapeutics at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of KROS. Barclays PLC boosted its stake in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the fourth quarter valued at approximately $388,000. Exchange Traded Concepts LLC bought a new position in Keros Therapeutics in the fourth quarter valued at approximately $99,000. China Universal Asset Management Co. Ltd. grew its holdings in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after acquiring an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB raised its position in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after acquiring an additional 1,100 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.
Keros Therapeutics Stock Down 1.6 %
Shares of NASDAQ:KROS traded down $0.22 during midday trading on Wednesday, reaching $13.54. The company had a trading volume of 338,413 shares, compared to its average volume of 812,332. The business's 50 day moving average price is $12.05 and its 200 day moving average price is $25.42. Keros Therapeutics, Inc. has a 1-year low of $9.12 and a 1-year high of $72.37. The stock has a market cap of $549.87 million, a PE ratio of -2.61 and a beta of 1.32.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period in the previous year, the firm earned ($1.21) EPS. On average, research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.
Insider Activity at Keros Therapeutics
In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 22.90% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Cantor Fitzgerald cut shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Truist Financial decreased their target price on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.33.
Check Out Our Latest Stock Analysis on KROS
About Keros Therapeutics
(
Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
